Zoetis (NYSE: ZTS) is one of 489 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Zoetis to similar businesses based on the strength of its profitability, dividends, institutional ownership, analyst recommendations, earnings, risk and valuation.
Institutional and Insider Ownership
92.6% of Zoetis shares are owned by institutional investors. Comparatively, 46.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 0.4% of Zoetis shares are owned by company insiders. Comparatively, 15.8% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
Zoetis has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Zoetis’ competitors have a beta of 1.09, suggesting that their average stock price is 9% more volatile than the S&P 500.
This is a summary of recent recommendations and price targets for Zoetis and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Zoetis currently has a consensus price target of $82.65, indicating a potential downside of 2.08%. As a group, “Pharmaceutical preparations” companies have a potential upside of 39.17%. Given Zoetis’ competitors higher possible upside, analysts clearly believe Zoetis has less favorable growth aspects than its competitors.
This table compares Zoetis and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Zoetis pays an annual dividend of $0.50 per share and has a dividend yield of 0.6%. Zoetis pays out 20.8% of its earnings in the form of a dividend. As a group, “Pharmaceutical preparations” companies pay a dividend yield of 2.2% and pay out 32.3% of their earnings in the form of a dividend. Zoetis has increased its dividend for 4 consecutive years.
Valuation & Earnings
This table compares Zoetis and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Zoetis||$5.31 billion||$864.00 million||35.17|
|Zoetis Competitors||$2.01 billion||$135.23 million||-3.60|
Zoetis has higher revenue and earnings than its competitors. Zoetis is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Zoetis beats its competitors on 9 of the 15 factors compared.
Zoetis Company Profile
Zoetis Inc. discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. In addition, the company offers other product categories, including nutritionals and agribusiness services, as well as products and services in complementary areas, such as biodevices, diagnostics, and genetics. It markets its products to veterinarians, livestock producers, and people who raise and care for farm and companion animals through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.